EODData

MEMBERSHIP REGISTER LOG IN

FRA, BT3: Lineage Cell Therapeutics Inc

21 Aug 2026
LAST:

0.9110

CHANGE:
 0.00		OPEN:
0.9110		HIGH:
0.9110		ASK:
0.0000		VOLUME:
0
CHG(%):
0.33		PREV:
0.9140		LOW:
0.9110		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Aug 260.91100.91100.91100.91100
20 Aug 260.91400.91400.91400.91400
19 Aug 260.89800.89800.89800.89800
18 Aug 260.88700.88700.88700.88700
17 Aug 260.89400.89400.89400.89400
14 Aug 260.89000.89000.89000.89000
13 Aug 260.92600.92600.92600.92600
12 Aug 260.94000.94000.94000.94000
07 Aug 260.94900.94900.94900.94900
06 Aug 260.95900.95900.95900.95900

PROFILE

Name:Lineage Cell Therapeutics Inc
About:Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Sector:Healthcare
Industry:Biotechnology
Address:2173 Salk Avenue, Carlsbad, CA, United States, 92008
Website:https://www.lineagecell.com
ISIN:US53566P1093
LEI:5299002BI4W22SDF8R25

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:5.39 
PEG Ratio:-0.05 
Price to Sales:17.61 
Price to Book:4.41 
Profit Margin:-2.47 
Operating Margin:-8.35 
Return on Assets:-0.17 
Return on Equity:-0.60 
Revenue:11.18M 
EBITDA:27.36M 
Shares:228.36M 
Market Cap:208.03M 

TECHNICAL INDICATORS

MA5:0.901.1%
MA10:0.920.6%
MA20:0.920.7%
MA50:1.0110.4%
MA100:1.1021.2%
MA200:1.2739.6%
STO9:38.71
STO14:33.33
RSI14:52.09
WPR14:-66.67
MTM14:-0.03
ROC14:-0.03 
ATR:0.02 
Week High:0.910.3%
Week Low:0.892.7%
Month High:0.976.5%
Month Low:0.8839.6%
Year High:1.6985.5%
Year Low:0.883.3%
Volatility:28.36 

RECENT SPLITS

Date Ratio
25 Nov 20191-3